Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Pharmacology
|
January 7, 2006
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
Reza Khosravan, Brian A Grabowski, Michael D Mayer, et al.
Current Medical Research and Opinion
|
March 16, 2007
Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use
Suzanne Novak, Arthur K Melkonian, Pankaj A Patel, et al.
The Journal of Rheumatology
|
December 7, 2005
Tophaceous gout: quantitative evaluation by direct physical measurement
H Ralph Schumacher, Michael A Becker, William A Palo, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society
|
September 23, 2021
Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
Jarrod P Holmes, Julio A Peguero, R Campbell Garland, et al.
Arthritis and Rheumatism
|
November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial
H Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 25, 2007
The impact of gout on work absence and productivity
Nathan L Kleinman, Richard A Brook, Pankaj A Patel, et al.
Current Medical Research and Opinion
|
July 13, 2006
The economic burden of gout on an employed population
Richard A Brook, Nathan L Kleinman, Pankaj A Patel, et al.
Arthritis and Rheumatism
|
March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
Michael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine
|
December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
Michael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The Journal of Rheumatology
|
June 7, 2007
Outcome evaluations in gout
H Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Pharmacology
|
January 7, 2006
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
Reza Khosravan, Brian A Grabowski, Michael D Mayer, et al.
Current Medical Research and Opinion
|
March 16, 2007
Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use
Suzanne Novak, Arthur K Melkonian, Pankaj A Patel, et al.
The Journal of Rheumatology
|
December 7, 2005
Tophaceous gout: quantitative evaluation by direct physical measurement
H Ralph Schumacher, Michael A Becker, William A Palo, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society
|
September 23, 2021
Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
Jarrod P Holmes, Julio A Peguero, R Campbell Garland, et al.
Arthritis and Rheumatism
|
November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial
H Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 25, 2007
The impact of gout on work absence and productivity
Nathan L Kleinman, Richard A Brook, Pankaj A Patel, et al.
Current Medical Research and Opinion
|
July 13, 2006
The economic burden of gout on an employed population
Richard A Brook, Nathan L Kleinman, Pankaj A Patel, et al.
Arthritis and Rheumatism
|
March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
Michael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine
|
December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
Michael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The Journal of Rheumatology
|
June 7, 2007
Outcome evaluations in gout
H Ralph Schumacher, William Taylor, Nancy Joseph-Ridge, et al.
Page
of 3